Charles River Laboratories International

CRL · NYSE

$315.45+$15.43 (+5.14%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $300.02

About CRL

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,300 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Employees: 18,300
Headquarters: Wilmington, Massachusetts
Listed: Jun 23, 2000
Sector: Health Care
Industry: Life Sciences Tools & Services
Website: criver.com

Leadership

Charles River Laboratories International executives
Name	Title	Since	Age
James Foster	—	1976	74
Michael Knell	—	—	49
Birgit Girshick	—	—	55
Victoria Creamer	—	—	55
Joseph LaPlume	—	—	51
Shannon Parisotto	—	—	51
Martin Mackay	—	—	69
Nancy Andrews	—	—	68
Steven Barg	—	—	62
Abraham Ceesay	—	—	47
Mark Enyedy	—	—	61
Paul Graves	—	—	54
Reshema Kemps-Polanco	—	—	52
George Llado	—	—	59
Craig Thompson	—	—	72
Virginia Wilson	—	—	70
Todd Spencer	—	2024	—

Revenue by product and region

Fiscal year ended Dec 27, 2025: $4.02B total revenue

By product

Service$3.25B80.9%
Product$765.28M19.1%

By region

U.S.$2.14B53.3%
Europe$1.10B27.5%
Canada$501.02M12.5%
Asia Pacific$205.02M5.1%
Other$64.86M1.6%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Charles River Laboratories International suppliers and customers
Company	Relationship	Country	Correlation
Spirax-Sarco Engineering SPX.L	Supplier and customer	GB	0.88
Harvard Bioscience HBIO	Supplier	US	0.86
Olix Pharmaceuticals	Supplier and customer	KR	0.85
Atara Biotherapeutics ATRA	Supplier and customer	US	0.78
Biotage BIOT.ST	Supplier	SE	0.68
Instem INS.L	Supplier	GB	0.66
First Wave Biopharma FWBI	Supplier and customer	US	0.62
Cellivery Therapeutics	Customer	KR	0.59
Avecho Biotechnology AVE.AX	Supplier and customer	AU	0.39
Simulations Plus SLP	Supplier	US	0.07

Similar companies

Companies in the same industry as Charles River Laboratories International

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.